Alaunos Therapeutics, Inc. (TCRT)
1.855
+0.02
(+0.82%)
USD |
NASDAQ |
Nov 06, 10:23
Alaunos Therapeutics EPS Diluted (Quarterly) : -0.4063 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.4063 |
| March 31, 2026 | -0.5928 |
| December 31, 2025 | -0.3988 |
| September 30, 2025 | -0.5502 |
| June 30, 2025 | -0.6347 |
| March 31, 2025 | -0.6701 |
| December 31, 2024 | -0.4634 |
| September 30, 2024 | -0.7038 |
| June 30, 2024 | -0.7051 |
| March 31, 2024 | -1.050 |
| December 31, 2023 | -4.898 |
| September 30, 2023 | -5.296 |
| June 30, 2023 | -5.488 |
| March 31, 2023 | -6.288 |
| December 31, 2022 | -6.15 |
| September 30, 2022 | -6.172 |
| June 30, 2022 | -6.93 |
| March 31, 2022 | -6.831 |
| December 31, 2021 | -8.241 |
| September 30, 2021 | -15.89 |
| June 30, 2021 | -15.86 |
| March 31, 2021 | -15.11 |
| December 31, 2020 | -16.04 |
| September 30, 2020 | -14.32 |
| June 30, 2020 | -13.11 |
| Date | Value |
|---|---|
| March 31, 2020 | -13.73 |
| December 31, 2019 | -13.16 |
| September 30, 2019 | -65.06 |
| June 30, 2019 | -13.64 |
| March 31, 2019 | -12.54 |
| December 31, 2018 | -12.75 |
| September 30, 2018 | -19.82 |
| June 30, 2018 | -18.00 |
| March 31, 2018 | -22.50 |
| December 31, 2017 | -19.50 |
| September 30, 2017 | -18.78 |
| June 30, 2017 | -19.50 |
| March 31, 2017 | -22.50 |
| December 31, 2016 | -16.50 |
| September 30, 2016 | -16.50 |
| June 30, 2016 | -151.50 |
| March 31, 2016 | -13.50 |
| December 31, 2015 | -10.50 |
| September 30, 2015 | -21.00 |
| June 30, 2015 | -16.50 |
| March 31, 2015 | -103.50 |
| December 31, 2014 | -15.16 |
| September 30, 2014 | -9.00 |
| June 30, 2014 | -9.00 |
| March 31, 2014 | -15.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Agenus, Inc. | -0.0146 |
| Amgen, Inc. | 7.077 |
| Anika Therapeutics, Inc. | 0.2412 |
| BioCryst Pharmaceuticals, Inc. | 0.1417 |
| Imunon, Inc. | -0.5412 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -0.952M |
| Total Expenses (Quarterly) | 0.952M |
| Enterprise Value | 4.450M |
| Earnings Yield | -105.0% |
| Normalized Earnings Yield | -105.02 |